{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:47:12Z","timestamp":1794271632074,"version":"4.9.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R21CA215591"],"award-info":[{"award-number":["R21CA215591"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"UT | University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["LLS 6680-24"],"award-info":[{"award-number":["LLS 6680-24"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR210029"],"award-info":[{"award-number":["RR210029"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["R37CA296577"],"award-info":[{"award-number":["R37CA296577"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22377068"],"award-info":[{"award-number":["22377068"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02698-1","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:00:51Z","timestamp":1780675251000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Histone deacetylase enzyme activity is not the universal anticancer target of HDAC inhibitors"],"prefix":"10.1038","volume":"11","author":[{"given":"Chaitra","family":"Rai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7506-3805","authenticated-orcid":false,"given":"Hang","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Hwan","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengchuang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6639-3746","authenticated-orcid":false,"given":"Udhaya","family":"Kumar. S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. James","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyin","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhandong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7380-2640","authenticated-orcid":false,"given":"Leng","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8346-9001","authenticated-orcid":false,"given":"Xuben","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6858-0633","authenticated-orcid":false,"given":"Zheng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"2698_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1615\/CritRevOncog.2015012997","volume":"20","author":"HP Chen","year":"2015","unstructured":"Chen, H. P., Zhao, Y. T. & Zhao, T. C. Histone deacetylases and mechanisms of regulation of gene expression. Crit. Rev. Oncog. 20, 35\u201347 (2015).","journal-title":"Crit. Rev. Oncog."},{"key":"2698_CR2","doi-asserted-by":"publisher","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","volume":"6","author":"E Seto","year":"2014","unstructured":"Seto, E. & Yoshida, M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb. Perspect. Biol. 6, a018713 (2014).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2698_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.sbi.2019.01.004","volume":"59","author":"NJ Porter","year":"2019","unstructured":"Porter, N. J. & Christianson, D. W. Structure, mechanism, and inhibition of the zinc-dependent histone deacetylases. Curr. Opin. Struct. Biol. 59, 9\u201318 (2019).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"2698_CR4","doi-asserted-by":"publisher","first-page":"17335","DOI":"10.1073\/pnas.0706487104","volume":"104","author":"A Lahm","year":"2007","unstructured":"Lahm, A. et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc. Natl. Acad. Sci. U.S.A. 104, 17335\u201317340 (2007).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2698_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1097-2765(01)00429-4","volume":"9","author":"W Fischle","year":"2002","unstructured":"Fischle, W. et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT\/N-CoR. Mol. Cell. 9, 45\u201357 (2002).","journal-title":"Mol. Cell."},{"key":"2698_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/icb.2011.100","volume":"90","author":"O Khan","year":"2012","unstructured":"Khan, O. & La Thangue, N. B. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell Biol. 90, 85\u201394 (2012).","journal-title":"Immunol. Cell Biol."},{"key":"2698_CR7","doi-asserted-by":"publisher","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","volume":"63","author":"TCS Ho","year":"2020","unstructured":"Ho, T. C. S., Chan, A. H. Y. & Ganesan, A. Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight. J. Med Chem. 63, 12460\u201312484 (2020).","journal-title":"J. Med Chem."},{"key":"2698_CR8","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1021\/mp200329f","volume":"8","author":"RW Robey","year":"2011","unstructured":"Robey, R. W. et al. Histone deacetylase inhibitors: emerging mechanisms of resistance. Mol. Pharm. 8, 2021\u20132031 (2011).","journal-title":"Mol. Pharm."},{"key":"2698_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","volume":"17","author":"M-Q Shi","year":"2024","unstructured":"Shi, M.-Q. et al. Advances in targeting histone deacetylase for treatment of solid tumors. J. Hematol. Oncol. 17, 37 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2698_CR10","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1517\/13543784.2011.613822","volume":"20","author":"J Knipstein","year":"2011","unstructured":"Knipstein, J. & Gore, L. Entinostat for treatment of solid tumors and hematologic malignancies. Expert Opin. Investig. Drugs. 20, 1455\u20131467 (2011).","journal-title":"Expert Opin. Investig. Drugs."},{"key":"2698_CR11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","volume":"42","author":"RR Shah","year":"2019","unstructured":"Shah, R. R. Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology. Drug Saf. 42, 235\u2013245 (2019).","journal-title":"Drug Saf."},{"key":"2698_CR12","doi-asserted-by":"publisher","first-page":"26926","DOI":"10.1074\/jbc.M113.490706","volume":"288","author":"BE Lauffer","year":"2013","unstructured":"Lauffer, B. E. et al. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. J. Biol. Chem. 288, 26926\u201343 (2013).","journal-title":"J. Biol. Chem."},{"key":"2698_CR13","doi-asserted-by":"publisher","first-page":"8072","DOI":"10.1093\/nar\/gkt590","volume":"41","author":"JP Lopez-Atalaya","year":"2013","unstructured":"Lopez-Atalaya, J. P., Ito, S., Valor, L. M., Benito, E. & Barco, A. Genomic targets, and histone acetylation and gene expression profiling of neural HDAC inhibition. Nucleic Acids Res. 41, 8072\u20138084 (2013).","journal-title":"Nucleic Acids Res."},{"key":"2698_CR14","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1038\/emboj.2010.235","volume":"29","author":"LH Kasper","year":"2010","unstructured":"Kasper, L. H. et al. CBP\/p300 double null cells reveal effect of coactivator level and diversity on CREB transactivation. EMBO J. 29, 3660\u20133672 (2010).","journal-title":"EMBO J."},{"key":"2698_CR15","doi-asserted-by":"publisher","first-page":"e33453","DOI":"10.1371\/journal.pone.0033453","volume":"7","author":"J Halsall","year":"2012","unstructured":"Halsall, J., Gupta, V., O\u2019Neill, L. P., Turner, B. M. & Nightingale, K. P. Genes are often sheltered from the global histone hyperacetylation induced by HDAC inhibitors. PLoS ONE. 7, e33453 (2012).","journal-title":"PLoS ONE."},{"key":"2698_CR16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.molcel.2013.10.022","volume":"52","author":"Z Sun","year":"2013","unstructured":"Sun, Z. et al. Deacetylase-independent function of HDAC3 in transcription and metabolism requires nuclear receptor corepressor. Mol. Cell 52, 769\u2013782 (2013).","journal-title":"Mol. Cell"},{"key":"2698_CR17","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1101\/gad.175950.111","volume":"25","author":"SE Mullican","year":"2011","unstructured":"Mullican, S. E. et al. Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation. Genes Dev. 25, 2480\u20132488 (2011).","journal-title":"Genes Dev."},{"key":"2698_CR18","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1038\/emboj.2010.136","volume":"29","author":"RH Wilting","year":"2010","unstructured":"Wilting, R. H. et al. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J. 29, 2586\u20132597 (2010).","journal-title":"EMBO J."},{"key":"2698_CR19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1021\/cr0206263","volume":"104","author":"G Parkin","year":"2004","unstructured":"Parkin, G. Synthetic analogues relevant to the structure and function of zinc enzymes. Chem. Rev. 104, 699\u2013767 (2004).","journal-title":"Chem. Rev."},{"key":"2698_CR20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1158\/2159-8290.CD-11-0181","volume":"1","author":"BS Taylor","year":"2011","unstructured":"Taylor, B. S. et al. Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas. Cancer Discov. 1, 587\u2013597 (2011).","journal-title":"Cancer Discov."},{"key":"2698_CR21","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/ng1773","volume":"38","author":"S Ropero","year":"2006","unstructured":"Ropero, S. et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat. Genet. 38, 566\u2013569 (2006).","journal-title":"Nat. Genet."},{"key":"2698_CR22","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.1038\/onc.2008.31","volume":"27","author":"S Ropero","year":"2008","unstructured":"Ropero, S. et al. Transforming pathways unleashed by a HDAC2 mutation in human cancer. Oncogene. 27, 4008\u20134012 (2008).","journal-title":"Oncogene."},{"key":"2698_CR23","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1158\/0008-5472.CAN-06-4152","volume":"67","author":"M Stark","year":"2007","unstructured":"Stark, M. & Hayward, N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 67, 2632\u20132642 (2007).","journal-title":"Cancer Res."},{"key":"2698_CR24","doi-asserted-by":"crossref","unstructured":"Ree, A. H., Folkvord, S. & Flatmark, K. HDAC2 deficiency and histone acetylation. Nat. Genet. 40, 812\u2013813 (2008).","DOI":"10.1038\/ng0708-812"},{"key":"2698_CR25","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1053\/j.gastro.2008.07.078","volume":"135","author":"CL Hanigan","year":"2008","unstructured":"Hanigan, C. L. et al. An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1. Gastroenterology. 135, 1654\u20131664.e2 (2008).","journal-title":"Gastroenterology."},{"key":"2698_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s13046-020-01783-9","volume":"39","author":"X-T Hu","year":"2020","unstructured":"Hu, X.-T. et al. HDAC2 inhibits EMT-mediated cancer metastasis by downregulating the long noncoding RNA H19 in colorectal cancer. J. Exp. Clin. Cancer Res 39, 270 (2020).","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"2698_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/ijc.20395","volume":"112","author":"H Osada","year":"2004","unstructured":"Osada, H. et al. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J. Cancer 112, 26\u201332 (2004).","journal-title":"Int J. Cancer"},{"key":"2698_CR28","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/mc.22345","volume":"55","author":"Z Lv","year":"2016","unstructured":"Lv, Z. et al. Downregulation of HDAC6 promotes angiogenesis in hepatocellular carcinoma cells and predicts poor prognosis in liver transplantation patients. Mol. Carcinog. 55, 1024\u20131033 (2016).","journal-title":"Mol. Carcinog."},{"key":"2698_CR29","doi-asserted-by":"publisher","first-page":"6962","DOI":"10.1158\/1078-0432.CCR-04-0455","volume":"10","author":"Z Zhang","year":"2004","unstructured":"Zhang, Z. et al. HDAC6 expression is correlated with better survival in breast cancer. Clin. Cancer Res 10, 6962\u20136968 (2004).","journal-title":"Clin. Cancer Res"},{"key":"2698_CR30","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1038\/emboj.2010.264","volume":"29","author":"S Lagger","year":"2010","unstructured":"Lagger, S. et al. Crucial function of histone deacetylase 1 for differentiation of teratomas in mice and humans. EMBO J. 29, 3992\u20134007 (2010).","journal-title":"EMBO J."},{"key":"2698_CR31","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/s41375-025-02584-9","volume":"39","author":"M Zrim\u0161ek","year":"2025","unstructured":"Zrim\u0161ek, M. et al. HDAC1 acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma: implications for HDAC inhibitor therapy. Leukemia 39, 1412\u20131424 (2025).","journal-title":"Leukemia"},{"key":"2698_CR32","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1182\/blood-2012-10-461988","volume":"121","author":"F Santoro","year":"2013","unstructured":"Santoro, F. et al. A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood. 121, 3459\u20133468 (2013).","journal-title":"Blood."},{"key":"2698_CR33","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ccr.2010.10.022","volume":"18","author":"S Bhaskara","year":"2010","unstructured":"Bhaskara, S. et al. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell. 18, 436\u2013447 (2010).","journal-title":"Cancer Cell."},{"key":"2698_CR34","doi-asserted-by":"publisher","first-page":"28021","DOI":"10.1074\/jbc.M113.498758","volume":"288","author":"C Song","year":"2013","unstructured":"Song, C., Zhu, S., Wu, C. & Kang, J. Histone deacetylase (HDAC) 10 suppresses cervical cancer metastasis through inhibition of matrix metalloproteinase (MMP) 2 and 9 expression. J. Biol. Chem. 288, 28021\u201328033 (2013).","journal-title":"J. Biol. Chem."},{"key":"2698_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12222-5","volume":"10","author":"PL Leslie","year":"2019","unstructured":"Leslie, P. L. et al. Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes. Nat. Commun. 10, 4192 (2019).","journal-title":"Nat. Commun."},{"key":"2698_CR36","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/hep.25699","volume":"56","author":"KH Jung","year":"2012","unstructured":"Jung, K. H. et al. Histone deacetylase 6 functions as a tumor suppressor by activating c-Jun NH2-terminal kinase-mediated beclin 1-dependent autophagic cell death in liver cancer. Hepatology 56, 644\u2013657 (2012).","journal-title":"Hepatology"},{"key":"2698_CR37","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.21037\/tcr-24-23","volume":"13","author":"J Xie","year":"2024","unstructured":"Xie, J., Liu, R., Cai, Y. & Liu, D. HDAC1: a promising target for cancer treatment: insights from a thorough analysis of tumor functions. Transl. Cancer Res 13, 5300\u20135315 (2024).","journal-title":"Transl. Cancer Res"},{"key":"2698_CR38","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202101742RR","volume":"36","author":"R Li","year":"2022","unstructured":"Li, R., Wu, X., Zhao, P., Xue, K. & Li, J. A pan-cancer analysis identifies HDAC11 as an immunological and prognostic biomarker. FASEB J. 36, e22326 (2022).","journal-title":"FASEB J."},{"key":"2698_CR39","doi-asserted-by":"publisher","first-page":"65","DOI":"10.21037\/tcr-23-1228","volume":"13","author":"H Chen","year":"2024","unstructured":"Chen, H. et al. A pancancer analysis of histone deacetylase 3 in human tumors. Transl. Cancer Res 13, 65\u201380 (2024).","journal-title":"Transl. Cancer Res"},{"key":"2698_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-023-02196-2","volume":"40","author":"Z Zhou","year":"2023","unstructured":"Zhou, Z. et al. HDAC11 mediates the ubiquitin-dependent degradation of p53 and inhibits the anti-leukemia effect of PD0166285. Med Oncol. 40, 325 (2023).","journal-title":"Med Oncol."},{"key":"2698_CR41","unstructured":"ICGC\/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578, 82\u201393 (2020)."},{"key":"2698_CR42","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1126\/science.aan5951","volume":"359","author":"D Miao","year":"2018","unstructured":"Miao, D. et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359, 801\u2013806 (2018).","journal-title":"Science"},{"key":"2698_CR43","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41586-021-04278-5","volume":"601","author":"S-J Sammut","year":"2022","unstructured":"Sammut, S.-J. et al. Multi-omic machine learning predictor of breast cancer therapy response. Nature. 601, 623\u2013629 (2022).","journal-title":"Nature."},{"key":"2698_CR44","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1038\/s41588-024-01785-9","volume":"56","author":"B Kinnersley","year":"2024","unstructured":"Kinnersley, B. et al. Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology. Nat. Genet 56, 1868\u20131877 (2024).","journal-title":"Nat. Genet"},{"key":"2698_CR45","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41586-024-08167-5","volume":"636","author":"J Jee","year":"2024","unstructured":"Jee, J. et al. Automated real-world data integration improves cancer outcome prediction. Nature. 636, 728\u2013736 (2024).","journal-title":"Nature."},{"key":"2698_CR46","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/s43018-024-00756-7","volume":"5","author":"S Sinha","year":"2024","unstructured":"Sinha, S. et al. PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors. Nat. Cancer 5, 938\u2013952 (2024).","journal-title":"Nat. Cancer"},{"key":"2698_CR47","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.cell.2024.11.010","volume":"188","author":"M Zucker","year":"2025","unstructured":"Zucker, M. et al. Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer. Cell 188, 851\u2013867.e17 (2025).","journal-title":"Cell"},{"key":"2698_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1523034","volume":"15","author":"J Zhang","year":"2024","unstructured":"Zhang, J. et al. Pan-cancer analysis of the transcriptional expression of histone acetylation enzymes in solid tumors defines a new classification scheme for gliomas. Front Immunol. 15, 1523034 (2024).","journal-title":"Front Immunol."},{"key":"2698_CR49","doi-asserted-by":"publisher","first-page":"339","DOI":"10.15171\/apb.2017.041","volume":"7","author":"B Mansoori","year":"2017","unstructured":"Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S. & Baradaran, B. The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv. Pharm. Bull. 7, 339\u2013348 (2017).","journal-title":"Adv. Pharm. Bull."},{"key":"2698_CR50","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nprot.2017.016","volume":"12","author":"J Joung","year":"2017","unstructured":"Joung, J. et al. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat. Protoc. 12, 828\u2013863 (2017).","journal-title":"Nat. Protoc."},{"key":"2698_CR51","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1101\/gr.245571.118","volume":"29","author":"H-H Jeong","year":"2019","unstructured":"Jeong, H.-H., Kim, S. Y., Rousseaux, M. W. C., Zoghbi, H. Y. & Liu, Z. Beta-binomial modeling of CRISPR pooled screen data identifies target genes with greater sensitivity and fewer false negatives. Genome Res 29, 999\u20131008 (2019).","journal-title":"Genome Res"},{"key":"2698_CR52","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.3892\/mmr.2015.3268","volume":"11","author":"J Ma","year":"2015","unstructured":"Ma, J. et al. Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and promotes apoptosis of esophageal squamous cell lines. Mol. Med Rep. 11, 4525\u20134531 (2015).","journal-title":"Mol. Med Rep."},{"key":"2698_CR53","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1128\/MCB.25.5.1608-1619.2005","volume":"25","author":"H Duan","year":"2005","unstructured":"Duan, H., Heckman, C. A. & Boxer, L. M. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol. Cell Biol. 25, 1608\u20131619 (2005).","journal-title":"Mol. Cell Biol."},{"key":"2698_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.9","volume":"4","author":"JE Bolden","year":"2013","unstructured":"Bolden, J. E. et al. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis. 4, e519 (2013).","journal-title":"Cell Death Dis."},{"key":"2698_CR55","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1158\/2159-8290.CD-12-0417","volume":"3","author":"L He","year":"2013","unstructured":"He, L. et al. Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma. Cancer Discov. 3, 324\u2013337 (2013).","journal-title":"Cancer Discov."},{"key":"2698_CR56","first-page":"5287","volume":"34","author":"N Kunami","year":"2014","unstructured":"Kunami, N., Katsuya, H., Nogami, R., Ishitsuka, K. & Tamura, K. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia\/lymphoma. Anticancer Res 34, 5287\u20135294 (2014).","journal-title":"Anticancer Res"},{"key":"2698_CR57","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1182\/blood-2017-06-792150","volume":"130","author":"BM Cyrenne","year":"2017","unstructured":"Cyrenne, B. M. et al. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. Blood 130, 2073\u20132083 (2017).","journal-title":"Blood"},{"key":"2698_CR58","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1124\/mol.109.056309","volume":"76","author":"AP Martin","year":"2009","unstructured":"Martin, A. P. et al. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Mol. Pharm. 76, 327\u2013341 (2009).","journal-title":"Mol. Pharm."},{"key":"2698_CR59","doi-asserted-by":"publisher","first-page":"445","DOI":"10.18632\/genesandcancer.42","volume":"5","author":"LME Berghauser Pont","year":"2014","unstructured":"Berghauser Pont, L. M. E. et al. The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells. Genes Cancer 5, 445\u2013459 (2014).","journal-title":"Genes Cancer"},{"key":"2698_CR60","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s41416-019-0394-9","volume":"120","author":"S Citro","year":"2019","unstructured":"Citro, S. et al. Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for \u0394Np63\u03b1. Br. J. Cancer 120, 658\u2013667 (2019).","journal-title":"Br. J. Cancer"},{"key":"2698_CR61","doi-asserted-by":"publisher","first-page":"523","DOI":"10.4161\/cbt.7.4.5480","volume":"7","author":"M Oua\u00efssi","year":"2008","unstructured":"Oua\u00efssi, M. et al. Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors. Cancer Biol. Ther. 7, 523\u2013531 (2008).","journal-title":"Cancer Biol. Ther."},{"key":"2698_CR62","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/bjc.2013.392","volume":"109","author":"J Moreaux","year":"2013","unstructured":"Moreaux, J. et al. Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. Br. J. Cancer 109, 676\u2013685 (2013).","journal-title":"Br. J. Cancer"},{"key":"2698_CR63","doi-asserted-by":"publisher","first-page":"djv247","DOI":"10.1093\/jnci\/djv247","volume":"107","author":"P Geeleher","year":"2015","unstructured":"Geeleher, P. et al. Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics. J. Natl. Cancer Inst. 107, djv247 (2015).","journal-title":"J. Natl. Cancer Inst."},{"key":"2698_CR64","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.3390\/cancers13153862","volume":"13","author":"C Mayr","year":"2021","unstructured":"Mayr, C. et al. HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer. Cancers (Basel) 13, 3862 (2021).","journal-title":"Cancers (Basel)"},{"key":"2698_CR65","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/cancers14010187","volume":"14","author":"S Behnisch-Cornwell","year":"2021","unstructured":"Behnisch-Cornwell, S. et al. Correlation Analysis of Protein Expression of 10 HDAC\/Sirtuin Isoenzymes with Sensitivities of 23 Anticancer Drugs in 17 Cancer Cell Lines and Potentiation of Drug Activity by Co-Treatment with HDAC Inhibitors. Cancers (Basel) 14, 187 (2021).","journal-title":"Cancers (Basel)"},{"key":"2698_CR66","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ccr.2008.12.001","volume":"15","author":"S Fotheringham","year":"2009","unstructured":"Fotheringham, S. et al. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 15, 57\u201366 (2009).","journal-title":"Cancer Cell"},{"key":"2698_CR67","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/bit.28611","volume":"121","author":"D Kim","year":"2024","unstructured":"Kim, D., Kim, S. H., Yoon, C. & Lee, G. M. Genome-wide CRISPR\/Cas9 knockout screening to mitigate cell growth inhibition induced by histone deacetylase inhibitors in recombinant CHO cells. Biotechnol. Bioeng. 121, 931\u2013941 (2024).","journal-title":"Biotechnol. Bioeng."},{"key":"2698_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-13-57","volume":"13","author":"Y Cai","year":"2013","unstructured":"Cai, Y. et al. The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms. Cancer Cell Int. 13, 57 (2013).","journal-title":"Cancer Cell Int."},{"key":"2698_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103457","volume":"69","author":"H Yang","year":"2021","unstructured":"Yang, H. et al. Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer. EBioMedicine 69, 103457 (2021).","journal-title":"EBioMedicine"},{"key":"2698_CR70","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1128\/MCB.00639-15","volume":"36","author":"A Hagelkruys","year":"2016","unstructured":"Hagelkruys, A. et al. Essential Nonredundant Function of the Catalytic Activity of Histone Deacetylase 2 in Mouse Development. Mol. Cell Biol. 36, 462\u2013474 (2016).","journal-title":"Mol. Cell Biol."},{"key":"2698_CR71","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/npp.2016.274","volume":"42","author":"JL Kwapis","year":"2017","unstructured":"Kwapis, J. L. et al. Context and Auditory Fear are Differentially Regulated by HDAC3 Activity in the Lateral and Basal Subnuclei of the Amygdala. Neuropsychopharmacology. 42, 1284\u20131294 (2017).","journal-title":"Neuropsychopharmacology."},{"key":"2698_CR72","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1432-0436.2007.00232.x","volume":"76","author":"GW Humphrey","year":"2008","unstructured":"Humphrey, G. W. et al. Complementary roles for histone deacetylases 1, 2, and 3 in differentiation of pluripotent stem cells. Differentiation 76, 348\u2013356 (2008).","journal-title":"Differentiation"},{"key":"2698_CR73","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1139\/O07-145","volume":"85","author":"A Sekhavat","year":"2007","unstructured":"Sekhavat, A., Sun, J.-M. & Davie, J. R. Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate. Biochem Cell Biol. 85, 751\u2013758 (2007).","journal-title":"Biochem Cell Biol."},{"key":"2698_CR74","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1128\/MCB.00494-07","volume":"27","author":"S Senese","year":"2007","unstructured":"Senese, S. et al. Role for histone deacetylase 1 in human tumor cell proliferation. Mol. Cell Biol. 27, 4784\u20134795 (2007).","journal-title":"Mol. Cell Biol."},{"key":"2698_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107231","volume":"26","author":"F Oger","year":"2023","unstructured":"Oger, F. et al. Pharmacological HDAC inhibition impairs pancreatic \u03b2-cell function through an epigenome-wide reprogramming. iScience 26, 107231 (2023).","journal-title":"iScience"},{"key":"2698_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00772-5","volume":"8","author":"SM Armour","year":"2017","unstructured":"Armour, S. M. et al. An HDAC3-PROX1 corepressor module acts on HNF4\u03b1 to control hepatic triglycerides. Nat. Commun. 8, 549 (2017).","journal-title":"Nat. Commun."},{"key":"2698_CR77","doi-asserted-by":"crossref","first-page":"D58","DOI":"10.1093\/nar\/gkaa197","volume":"48","author":"T Gao","year":"2020","unstructured":"Gao, T. & Qian, J. EnhancerAtlas 2.0: an updated resource with enhancer annotation in 586 tissue\/cell types across nine species. Nucleic Acids Res 48, D58\u2013D64 (2020).","journal-title":"Nucleic Acids Res"},{"key":"2698_CR78","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.ajpath.2013.12.002","volume":"184","author":"X Chen","year":"2014","unstructured":"Chen, X. & Calvisi, D. F. Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am. J. Pathol. 184, 912\u2013923 (2014).","journal-title":"Am. J. Pathol."},{"key":"2698_CR79","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1146\/annurev-pathol-020117-044010","volume":"13","author":"JO Russell","year":"2018","unstructured":"Russell, J. O. & Monga, S. P. Wnt\/\u03b2-Catenin Signaling in Liver Development, Homeostasis, and Pathobiology. Annu Rev. Pathol. 13, 351\u2013378 (2018).","journal-title":"Annu Rev. Pathol."},{"key":"2698_CR80","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/hep.29496","volume":"67","author":"M Bouattour","year":"2018","unstructured":"Bouattour, M. et al. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma. Hepatology 67, 1132\u20131149 (2018).","journal-title":"Hepatology"},{"key":"2698_CR81","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4254\/wjh.v2.i1.16","volume":"2","author":"C-P Lin","year":"2010","unstructured":"Lin, C.-P., Liu, C.-R., Lee, C.-N., Chan, T.-S. & Liu, H. E. Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J. Hepatol. 2, 16\u201320 (2010).","journal-title":"World J. Hepatol."},{"key":"2698_CR82","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1002\/hep.28601","volume":"64","author":"J Tao","year":"2016","unstructured":"Tao, J. et al. Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant \u03b2-catenin. Hepatology 64, 1587\u20131605 (2016).","journal-title":"Hepatology"},{"key":"2698_CR83","doi-asserted-by":"publisher","first-page":"6621","DOI":"10.1016\/j.bmcl.2012.08.104","volume":"22","author":"AS Vaidya","year":"2012","unstructured":"Vaidya, A. S. et al. Novel histone deacetylase 8 ligands without a zinc chelating group: exploring an \u2018upside-down\u2019 binding pose. Bioorg. Med Chem. Lett. 22, 6621\u20136627 (2012).","journal-title":"Bioorg. Med Chem. Lett."},{"key":"2698_CR84","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.bmcl.2007.01.117","volume":"17","author":"AV Bieliauskas","year":"2007","unstructured":"Bieliauskas, A. V., Weerasinghe, S. V. W. & Pflum, M. K. H. Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid. Bioorg. Med Chem. Lett. 17, 2216\u20132219 (2007).","journal-title":"Bioorg. Med Chem. Lett."},{"key":"2698_CR85","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/ardp.201500472","volume":"349","author":"AV Bieliauskas","year":"2016","unstructured":"Bieliauskas, A. V., Weerasinghe, S. V. W., Negmeldin, A. T. & Pflum, M. K. H. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid. Arch. Pharm. (Weinh.) 349, 373\u2013382 (2016).","journal-title":"Arch. Pharm. (Weinh.)"},{"key":"2698_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1152035","volume":"14","author":"NJ Shields","year":"2023","unstructured":"Shields, N. J. et al. Late-stage MC38 tumours recapitulate features of human colorectal cancer - implications for appropriate timepoint selection in preclinical studies. Front Immunol. 14, 1152035 (2023).","journal-title":"Front Immunol."},{"key":"2698_CR87","doi-asserted-by":"publisher","first-page":"16480","DOI":"10.1021\/acs.jmedchem.4c01310","volume":"67","author":"Y Chang","year":"2024","unstructured":"Chang, Y. et al. Development of a First-in-Class DNMT1\/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity. J. Med Chem. 67, 16480\u201316504 (2024).","journal-title":"J. Med Chem."},{"key":"2698_CR88","doi-asserted-by":"publisher","first-page":"e0153053","DOI":"10.1371\/journal.pone.0153053","volume":"11","author":"KN Kodumudi","year":"2016","unstructured":"Kodumudi, K. N. et al. Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy. PLoS One 11, e0153053 (2016).","journal-title":"PLoS One"},{"key":"2698_CR89","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1016\/j.celrep.2018.05.050","volume":"23","author":"D Wang","year":"2018","unstructured":"Wang, D. et al. Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity. Cell Rep. 23, 3262\u20133274 (2018).","journal-title":"Cell Rep."},{"key":"2698_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215780","volume":"543","author":"C-H Song","year":"2022","unstructured":"Song, C.-H. et al. Combination treatment with 17\u03b2-estradiol and anti-PD-L1 suppresses MC38 tumor growth by reducing PD-L1 expression and enhancing M1 macrophage population in MC38 colon tumor model. Cancer Lett. 543, 215780 (2022).","journal-title":"Cancer Lett."},{"key":"2698_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-2-67","volume":"2","author":"MJ LaBonte","year":"2009","unstructured":"LaBonte, M. J. et al. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med Genomics 2, 67 (2009).","journal-title":"BMC Med Genomics"},{"key":"2698_CR92","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1158\/1535-7163.MCT-07-2353","volume":"7","author":"S Roy","year":"2008","unstructured":"Roy, S., Jeffrey, R. & Tenniswood, M. Array-based analysis of the effects of trichostatin A and CG-1521 on cell cycle and cell death in LNCaP prostate cancer cells. Mol. Cancer Ther. 7, 1931\u20131939 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"2698_CR93","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S1535-6108(03)00165-X","volume":"4","author":"RW Johnstone","year":"2003","unstructured":"Johnstone, R. W. & Licht, J. D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4, 13\u201318 (2003).","journal-title":"Cancer Cell"},{"key":"2698_CR94","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1210\/me.2008-0179","volume":"23","author":"SE Wardell","year":"2009","unstructured":"Wardell, S. E. et al. Glucose metabolism as a target of histone deacetylase inhibitors. Mol. Endocrinol. 23, 388\u2013401 (2009).","journal-title":"Mol. Endocrinol."},{"key":"2698_CR95","doi-asserted-by":"publisher","first-page":"e4363","DOI":"10.1371\/journal.pone.0004363","volume":"4","author":"P Gupta","year":"2009","unstructured":"Gupta, P., Ho, P.-C., Ha, S. G., Lin, Y.-W. & Wei, L.-N. HDAC3 as a molecular chaperone for shuttling phosphorylated TR2 to PML: a novel deacetylase activity-independent function of HDAC3. PLoS ONE 4, e4363 (2009).","journal-title":"PLoS ONE"},{"key":"2698_CR96","doi-asserted-by":"publisher","first-page":"5106","DOI":"10.1093\/nar\/gkab313","volume":"49","author":"H Yin","year":"2021","unstructured":"Yin, H. et al. HDAC3 controls male fertility through enzyme-independent transcriptional regulation at the meiotic exit of spermatogenesis. Nucleic Acids Res 49, 5106\u20135123 (2021).","journal-title":"Nucleic Acids Res"},{"key":"2698_CR97","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nsmb.2476","volume":"20","author":"S-H You","year":"2013","unstructured":"You, S.-H. et al. Nuclear receptor co-repressors are required for the histone-deacetylase activity of HDAC3 in vivo. Nat. Struct. Mol. Biol. 20, 182\u2013187 (2013).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2698_CR98","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cell.2017.09.018","volume":"171","author":"A Poleshko","year":"2017","unstructured":"Poleshko, A. et al. Genome-Nuclear Lamina Interactions Regulate Cardiac Stem Cell Lineage Restriction. Cell 171, 573\u2013587.e14 (2017).","journal-title":"Cell"},{"key":"2698_CR99","doi-asserted-by":"publisher","first-page":"27067","DOI":"10.1074\/jbc.M115.684753","volume":"290","author":"SL Lewandowski","year":"2015","unstructured":"Lewandowski, S. L., Janardhan, H. P. & Trivedi, C. M. Histone Deacetylase 3 Coordinates Deacetylase-independent Epigenetic Silencing of Transforming Growth Factor-\u03b21 (TGF-\u03b21) to Orchestrate Second Heart Field Development. J. Biol. Chem. 290, 27067\u201327089 (2015).","journal-title":"J. Biol. Chem."},{"key":"2698_CR100","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/jcp.30957","volume":"238","author":"J Ren","year":"2023","unstructured":"Ren, J. et al. Deacetylase-dependent and -independent role of HDAC3 in cardiomyopathy. J. Cell Physiol. 238, 647\u2013658 (2023).","journal-title":"J. Cell Physiol."},{"key":"2698_CR101","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1016\/j.apsb.2025.05.002","volume":"15","author":"S Qian","year":"2025","unstructured":"Qian, S. et al. Enzyme-independent functions of HDAC3 in the adult heart. Acta Pharm. Sin. B 15, 3561\u20133574 (2025).","journal-title":"Acta Pharm. Sin. B"},{"key":"2698_CR102","doi-asserted-by":"publisher","first-page":"e0202935","DOI":"10.1371\/journal.pone.0202935","volume":"13","author":"H Jung","year":"2018","unstructured":"Jung, H. et al. Deacetylase activity-independent transcriptional activation by HDAC2 during TPA-induced HL-60 cell differentiation. PLoS One 13, e0202935 (2018).","journal-title":"PLoS One"},{"key":"2698_CR103","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1359\/jbmr.071104","volume":"23","author":"ED Jensen","year":"2008","unstructured":"Jensen, E. D., Schroeder, T. M., Bailey, J., Gopalakrishnan, R. & Westendorf, J. J. Histone deacetylase 7 associates with Runx2 and represses its activity during osteoblast maturation in a deacetylation-independent manner. J. Bone Min. Res 23, 361\u2013372 (2008).","journal-title":"J. Bone Min. Res"},{"key":"2698_CR104","doi-asserted-by":"publisher","first-page":"22491","DOI":"10.1074\/jbc.M100206200","volume":"276","author":"H Brinkmann","year":"2001","unstructured":"Brinkmann, H. et al. Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts. J. Biol. Chem. 276, 22491\u201322499 (2001).","journal-title":"J. Biol. Chem."},{"key":"2698_CR105","doi-asserted-by":"publisher","first-page":"11810","DOI":"10.3390\/ijms222111810","volume":"22","author":"M Halasa","year":"2021","unstructured":"Halasa, M. et al. Deacetylation of Transcription Factors in Carcinogenesis. Int J. Mol. Sci. 22, 11810 (2021).","journal-title":"Int J. Mol. Sci."},{"key":"2698_CR106","doi-asserted-by":"publisher","first-page":"e7663","DOI":"10.1097\/MD.0000000000007663","volume":"96","author":"L-L Cao","year":"2017","unstructured":"Cao, L.-L. et al. Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysis. Med. (Baltim.) 96, e7663 (2017).","journal-title":"Med. (Baltim.)"},{"key":"2698_CR107","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1158\/0008-5472.CAN-20-3044","volume":"81","author":"L Bi","year":"2021","unstructured":"Bi, L. et al. HDAC11 Regulates Glycolysis through the LKB1\/AMPK Signaling Pathway to Maintain Hepatocellular Carcinoma Stemness. Cancer Res 81, 2015\u20132028 (2021).","journal-title":"Cancer Res"},{"key":"2698_CR108","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3390\/cancers12020412","volume":"12","author":"SS Oltra","year":"2020","unstructured":"Oltra, S. S. et al. HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women. Cancers (Basel) 12, 412 (2020).","journal-title":"Cancers (Basel)"},{"key":"2698_CR109","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.3390\/ijms20071616","volume":"20","author":"W Li","year":"2019","unstructured":"Li, W. & Sun, Z. Mechanism of Action for HDAC Inhibitors-Insights from Omics Approaches. Int. J. Mol. Sci. 20, 1616 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"2698_CR110","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1126\/science.aao3265","volume":"358","author":"X Gu","year":"2017","unstructured":"Gu, X. et al. SAMTOR is an S-adenosylmethionine sensor for the mTORC1 pathway. Science 358, 813\u2013818 (2017).","journal-title":"Science"},{"key":"2698_CR111","doi-asserted-by":"publisher","first-page":"14771","DOI":"10.1073\/pnas.0706578104","volume":"104","author":"AD Tward","year":"2007","unstructured":"Tward, A. D. et al. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc. Natl. Acad. Sci. USA 104, 14771\u201314776 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2698_CR112","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/ng.343","volume":"41","author":"L M\u00e1t\u00e9s","year":"2009","unstructured":"M\u00e1t\u00e9s, L. et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat. Genet 41, 753\u2013761 (2009).","journal-title":"Nat. Genet"},{"key":"2698_CR113","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","volume":"9","author":"M Ruiz de Galarreta","year":"2019","unstructured":"Ruiz de Galarreta, M. et al. \u03b2-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. Cancer Discov. 9, 1124\u20131141 (2019).","journal-title":"Cancer Discov."},{"key":"2698_CR114","doi-asserted-by":"crossref","unstructured":"ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 489, 57\u201374 (2012).","DOI":"10.1038\/nature11247"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02698-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02698-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02698-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:04:11Z","timestamp":1780679051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02698-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":114,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2698"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02698-1","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"218"}}